Form 4: Adaptive Biotechnologies Exec Sells Shares Under 10b5-1 Plan

Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp, reported the sale of 10,000 shares of common stock for $148,500, executed under a pre-arranged trading plan.

Summary

• Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corporation, sold 10,000 shares of common stock.
• The transaction occurred on April 8, 2026, with a weighted-average sale price of $14.85 per share, totaling $148,500.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on August 11, 2025.
• Following the transaction, Mr. Robins beneficially owns 1,512,058 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be a negative signal, the execution under a pre-established 10b5-1 plan and the retention of a substantial number of shares temper this concern.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider trading related activity.
• The reporting person retains a significant beneficial ownership of 1,512,058 shares, suggesting continued commitment to the company.

Negatives

• A significant number of shares (10,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale price range was between $14.65 and $15.06, indicating the sale occurred at a price point that may be of interest to investors.

Risks

• The sale of shares by a Chief Scientific Officer could be interpreted as a lack of confidence in future stock performance, although it was conducted under a 10b5-1 plan.
• The specific price range of the sales ($14.65 to $15.06) might indicate a level of price sensitivity for the executive's divestment.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on a past transaction.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
• The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $14.65 to $15.06, inclusive.
• The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by investors. While these plans are designed to mitigate concerns about insider trading, significant sales by key executives can still influence market perception and stock price, especially in the biotechnology sector where executive confidence is a key indicator.

Stakeholder Impact

• Shareholders: May view the sale with caution, although the 10b5-1 plan mitigates concerns about non-public information. The significant remaining ownership by the executive may provide some reassurance.
• Employees: May interpret the sale as a signal about the company's future prospects, though the context of the 10b5-1 plan is important.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The reporting person may provide further details on specific sale prices upon request from the SEC, Adaptive Biotechnologies Corporation, or any security holder.

Key Dates

Recommendation

The filing reports a routine stock sale by an executive under a 10b5-1 plan. While insider selling can be a negative indicator, the pre-planned nature and the executive's substantial remaining ownership suggest this is likely a personal financial management decision rather than a reflection of negative company outlook. Therefore, a 'hold' recommendation is appropriate, pending further company performance data.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Harlan S. Robins, Chief Scientific Officer, Beneficial Ownership